Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
Acta Pharmaceutica Sinica B, 2022 The proteolysis targeting chimeras (PROTACs) technology has been rapidly developed since its birth in 2001, attracting rapidly growing attention of scientific institutes and pharmaceutical companies.
Xiao-Li Xu, Qi-Dong You, Zheng-Yu Jiang
exaly +5 more sources
PROTACs: The Future of Leukemia Therapeutics
Frontiers in Cell and Developmental Biology, 2022 The fight to find effective, long-lasting treatments for cancer has led many researchers to consider protein degrading entities. Recent developments in PROteolysis TArgeting Chimeras (PROTACs) have signified their potential as possible cancer therapies ...
Zubair Anwar +6 more
doaj +4 more sources
pH-Activatable engineered nanoparticle-based selective hexokinase 2 degrader provokes GSDME-dependent pyroptosis for cancer therapy [PDF]
Acta Pharmaceutica Sinica BProteolysis targeting chimeras (PROTACs) technology has been developed as an exquisite promising approach for targeted protein degradation by hijacking the cellular ubiquitin-proteasome system (UPS).
Linlin Gong +9 more
doaj +2 more sources
PROTAC-based protein degradation: a window of opportunity for melanoma therapy [PDF]
Journal of Biomedical ScienceThe key small molecule-based modalities for inducing targeted protein degradation have seen explosive growth over the past decade. They include heterobifunctional degraders such as PROteolysis TArgeting Chimeras (PROTACs): molecules working as protein ...
Giulia Gentile +6 more
doaj +2 more sources
Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents
Journal of Enzyme Inhibition and Medicinal Chemistry, 2022 Proteolytic targeting chimaeras (PROTACs) have been developed as an effective technology for targeted protein degradation. PROTACs are heterobifunctional molecules that can trigger the polyubiquitination of proteins of interest (POIs) by recruiting the ...
Dong-Ming Xing
exaly +3 more sources
PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
Molecules, 2023 A potential therapeutic strategy to treat conditions brought on by the aberrant production of a disease-causing protein is emerging for targeted protein breakdown using the PROTACs technology.
Krishnan Anand, Sumel Ashique
exaly +3 more sources
Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
Molecules, 2022 The PROteolysis TArgeting Chimeras (PROTACs) is an innovative technique for the selective degradation of target proteins via the ubiquitin–proteasome system.
Jiao Li
exaly +3 more sources
Nano-PROTACs for precision medicine: engineering strategies for enhanced targeting and potency [PDF]
Journal of NanobiotechnologyProteolysis-targeting chimeras (PROTACs) represent a transformative therapeutic modality that leverages the endogenous ubiquitin-proteasome system (UPS) to achieve targeted protein degradation.
Xiaoping Yang +9 more
doaj +2 more sources
Major Advances in Emerging Degrader Technologies
Frontiers in Cell and Developmental Biology, 2022 Recently, degrader technologies have attracted increasing interest in the academic field and the pharmaceuticals industry. As one of the degrader technologies, proteolysis-targeting chimeras (PROTACs) have emerged as an attractive pharmaceutical ...
Hang Luo +5 more
doaj +1 more source
An overview of PROTACs: a promising drug discovery paradigm
Molecular Biomedicine, 2022 Proteolysis targeting chimeras (PROTACs) technology has emerged as a novel therapeutic paradigm in recent years. PROTACs are heterobifunctional molecules that degrade target proteins by hijacking the ubiquitin–proteasome system.
Zi Liu +10 more
doaj +1 more source